WallStSmart

Codexis Inc (CDXS)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Codexis Inc generates 10425% more annual revenue ($78.09M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -41.0%. CDXS earns a higher WallStSmart Score of 34/100 (F).

CDXS

Avoid

34

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.7Quality: 5.5
Piotroski: 4/9Altman Z: -5.25

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CDXSUndervalued (+83.5%)

Margin of Safety

+83.5%

Fair Value

$7.19

Current Price

$2.56

$4.63 discount

UndervaluedFair: $7.19Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CDXS1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
102.1%10/10

Revenue surging 102.1% year-over-year

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

CDXS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$254.51M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.693/10

Elevated debt levels

PEG RatioValuation
13.532/10

Expensive relative to growth rate

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CDXS

The strongest argument for CDXS centers on Revenue Growth. Revenue growth of 102.1% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : CDXS

The primary concerns for CDXS are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.69 is elevated, increasing financial risk.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

CDXS profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

CDXS carries more volatility with a beta of 2.48 — expect wider price swings.

CDXS is growing revenue faster at 102.1% — sustainability is the question.

CDXS generates stronger free cash flow (-13M), providing more financial flexibility.

Bottom Line

CDXS scores higher overall (34/100 vs 24/100) and 102.1% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Codexis Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?